Osteoporosis

Estrogen patch for osteoporosis prevention currently under FDA review

Published in Medical Letter on the CDC and FDA, November 16th, 2003

Berlex Laboratories announced that the new drug application (NDA) seeking approval for a transdermal estrogen therapy for the prevention of osteoporosis, delivering 0.014 mg of estradiol each day, has been accepted for filing by the U.S. Food and Drug Administration (FDA).

This patch, under the proposed name Menostar, delivers nearly 50% less estrogen per day than the lowest dose transdermal estrogen product currently available for the prevention of osteoporosis.

Upon approval, Menostar will offer healthcare providers with a new treatment option that delivers an ultra-low dose of plant-based estrogen, which will not require a concomitant progestin,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry